Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 9 of the 27 sources its claims cite were checked for support.

Nitazenes: review of comparative pharmacology and antagonist action

Open access
Stangeland, Marcus, Dale, Ola, Skulberg, Arne Kristian · 2025 · Clinical Toxicology

Abstract

Introduction Nitazenes are a class of potent synthetic opioids that have emerged in illicit drug markets and have been identified in combination with other opioids in cases of poisoning and fatalities. Originally developed in the 1950s, these compounds were abandoned due to their high toxicity and unfavourable therapeutic index. Recent reports indicate that nitazenes exhibit a wide range of potencies, with some exceeding that of fentanyl. Understanding the pharmacological and toxicological profiles of nitazenes is critical for public health and clinical management. This review synthesizes literature on the pharmacology, toxicity, and antagonist action of nitazenes, particularly their response to naloxone.Methods A comprehensive literature review was conducted using EMBASE, Ovid MEDLINE(R), APA PsycInfo, Scopus, and Web of Science up to 26 July 2024. The main search terms used were: “nitazen*”, “2-benzylbenzimidazole”, “aminoisotonitazene” OR “butonitazeneor clonitazene” OR “desnitazene” OR “etodesnitazene” OR “etonitazene” OR “flunitazene” OR “isotonitazene” OR “metodesnitazene” OR “metonitazene” OR “protonitazene”. Inclusion criteria encompassed in vitro and animal studies, post-mortem toxicology, clinical trials, and case reports on nitazene poisoning. Data regarding naloxone dosing in confirmed cases of nitazene poisoning were also analyzed.Results We identified 1,383 studies, and after removing duplicates, 557 abstracts were screened. Based on the eligibility criteria, 78 articles underwent full-text screening, and 35 were included in the final review. Nitazenes exhibit variability in potency and toxicity. In vitro studies suggest that their receptor affinity and potency often surpass those of both morphine and fentanyl. Real-world data indicate that in vivo potency is often lower than experimental findings. Case reports and clinical series indicate that naloxone remains an effective antidote for nitazene poisoning. A median dose of parenteral naloxone 1.20 mg effectively reversed poisoning, with a median dose of 0.8 mg in the pre-hospital setting. However, a subset of patients received prolonged naloxone infusions due to the persistence of opioid effects. Six out of 30 patients were treated with naloxone infusions. This ratio is higher than that reflected in current clinical guidelines, in which shorter observation time is deemed sufficient. Post-mortem toxicological analyses reveal highly variable nitazene concentrations, with overlap with those concentrations found in patients. This complicates the establishment of lethal thresholds. In several cases, nitazene metabolites were detected in isolation, suggesting independent pharmacological activity or alternative routes of administration. Additionally, nitazene poisoning often involves polysubstance use, further complicating diagnosis and management.Discussion Data on nitazene potency in humans are scarce. Nitazenes are a heterogeneous group with very high experimental potency compared to morphine. The potency in in vivo outcome studies in humans is far lower than that in in vitro studies. Post-mortem concentrations of many nitazenes are similar to the post-mortem concentrations of fentanyl and indicate a similar potency. Treatment of nitazene poisoning should follow the guidelines for opioid poisoning, that is, instituting airway management and administering naloxone. All cases reviewed had several opioids and other sedating drugs in addition to nitazenes in their analytical workup. The median parenteral dose for successful reversal of features was 1.20 mg. This finding provides reassurance that naloxone is effective for the treatment of poisoning due to nitazene as well as other potent opioids.Conclusions Nitazenes represent an emerging public health challenge due to their high potency, unknown pharmacokinetics, and increasing presence in illicit drug supplies. While naloxone is effective in reversing nitazene poisoning, cases of prolonged toxicity suggest the need for extended monitoring and repeated naloxone dosing. The findings of this review highlight the importance of enhanced drug surveillance, improved clinical awareness, and the development of targeted harm reduction strategies, including the potential for novel opioid antagonists with prolonged efficacy. Future research should focus on defining nitazene receptor kinetics, post-mortem redistribution effects, and optimizing naloxone administration protocols for these emerging synthetic opioids.

Overview

CoChat Summary

TL;DR

This systematic review synthesizes nitazene pharmacology, toxicity, and naloxone reversal, finding very high in vitro potency but substantially lower human in vivo potency and highly variable post-mortem concentrations. Naloxone remains effective, with a median parenteral reversal dose of 1.20 mg, though 6 of 30 patients required prolonged naloxone infusions.

Key findings

  • In vitro potency often exceeds morphine and fentanyl: metonitazene and isotonitazene exceeded fentanyl by approximately 6-fold and 125-fold, respectively; etonitazene’s in vitro antinociceptive potency was 1,000 times morphine, but its human euphoric effect was 80–120 times morphine. Metonitazene was 100 times morphine in vitro but only 10 times morphine in humans; clonitazene was 3 times morphine in vitro but one-third to one-half morphine in humans.
  • Among 30 analytically confirmed nitazene poisoning cases, median total parenteral naloxone dose was 1.20 mg (IQR 0.80–1.94 mg; n = 29); parenteral-route median was 0.80 mg (IQR 0.40–1.20 mg; n = 25). Six of 30 patients received prolonged naloxone infusions, and two of 30 died after cardiac arrest at presentation.
  • Post-mortem nitazene concentrations were variable and overlapped with patient concentrations: isotonitazene median 1.2–1.7 µg/L (range 0.4–9.5 µg/L), metonitazene median 3.8–6 µg/L (range <0.5–33 µg/L), and protonitazene peripheral blood 0.1–25 µg/L, with one central blood case at 1,400 µg/L. Fentanyl post-mortem median was 16 µg/L (range 1.3–200 µg/L; n = 824), and carfentanil median was 0.098 µg/L (range 0.01–2 µg/L; n = 262).
  • The review identified 1,383 studies; after duplicate removal, 557 abstracts were screened, and 35 articles were included in the final review. Nitazene poisoning often involved polysubstance use, and nitazene metabolites were sometimes detected in isolation.

Methods

  • Systematic literature search of EMBASE, Ovid MEDLINE, APA PsycInfo, Scopus, and Web of Science, plus citation searching and non-indexed sources, through 26 July 2024; search terms included “nitazen*” and individual nitazene names; articles in English and German; no search filters; Covidence and PRISMA used.
  • Inclusion covered in vitro and animal studies, post-mortem toxicology, clinical trials, case reports/case series, and policy documents; articles were included if they contained human nitazene concentrations, in vitro potency, or antagonism data, and excluded if limited to animals, lacked concentration data, or concerned analytical methodology. Two authors screened abstracts, all authors contributed to full-text review, and conflicts were resolved by discussion.
  • Descriptive synthesis; naloxone doses were summed and bioavailable doses calculated assuming 50% intranasal and 90% intramuscular bioavailability; analyses used Microsoft Excel and SigmaPlot 15.0, with normality assessed by Shapiro-Wilk and results reported as median and IQR unless otherwise specified.

Limitations

  • Stated: no randomized trials addressed the review’s objectives; many included studies used in vitro or post-mortem data, limiting clinical generalizability; no minimum standards or standardized formats exist for reporting naloxone dosing, routes, or timing between doses, making collation across case reports/series challenging.
  • Evident from the text: human potency data are scarce, samples were small case reports/series that may not represent a native population, post-mortem redistribution and interindividual tolerance complicate concentration comparisons, most poisonings involved other psychoactive drugs, and no receptor kinetics data for nitazenes were found.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/15563650.2025.2504133

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

2 Valid · 9 Not valid · 10 Not checked · 35 Own results and interpretations

31 more claims

Create a free account to see all 56 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 7
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. 10.1515/cclm-2023-136 · doi:10.1515/cclm-2023-136

Cited by

See all 34

Metadata

Authors
Stangeland, M., Dale, O., & Skulberg, A. K.
Affiliations
  • Haukeland University Hospital (NO)
  • Norwegian University of Science and Technology (NO)
  • Oslo University Hospital (NO)
Corresponding author
Skulberg, Arne Kristian
Venue
Clinical Toxicology
Published
2025-05-27
Volume
63
Issue
6
Pages
393-406
ISSN
  • 0009-9309 (ISSN-L)
  • 1556-3650
  • 1556-9519
OpenAlex
W4410779225
Cited by
34
References
53
Citations by year
2026: 22 · 2025: 12
FWCI
5.91
Type
journal article
Language
en
Open access
Locations
  • Clinical Toxicology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Haukeland University Hospital and Oslo University Hospital, Norway and the Norwegian University of Science and Technology
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
Keywords
nitazenes, synthetic opioids, opioid toxicity, naloxone, naloxone antagonism, opioid receptor affinity, opioid potency, postmortem toxicology, illicit drug markets, combination therapy, etonitazene
MeSH terms
Analgesics, Opioid, Animals, Humans, Naloxone, Narcotic Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nitazenes: review of comparative pharmacology and antagonist action. https://app.cochat.ai/papers/10.1080/15563650.2025.2504133
The paper
Stangeland, M., Dale, O., & Skulberg, A. K. (2025). Nitazenes: review of comparative pharmacology and antagonist action. Clinical Toxicology. https://doi.org/10.1080/15563650.2025.2504133

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.